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In Brief
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and serum limitation, which cause a
harmful increase in fatty acid saturation.
Studying kidney cancer, Ackerman et al.
describe a protective role of lipid droplet-
resident triglycerides: buffering of the
cellular lipid saturation through exchange
of mono-unsaturated fatty acids.
Inhibiting triglyceride synthesis
compromises solid tumor growth.
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Lipid droplets, which store triglycerides and choles-
terol esters, are a prominent feature of clear cell renal
cell carcinoma (ccRCC). Although their presence in
ccRCC is critical for sustained tumorigenesis, their
contribution to lipid homeostasis and tumor cell
viability is incompletely understood. Here we show
that disrupting triglyceride synthesis compromises
the growth of both ccRCC tumors and ccRCC cells
exposed to tumor-like conditions. Functionally, hyp-
oxia leads to increased fatty acid saturation through
inhibition of the oxygen-dependent stearoyl-CoA de-
saturase (SCD) enzyme. Triglycerides counter a toxic
buildup of saturated lipids, primarily by releasing the
unsaturated fatty acid oleate (the principal product of
SCD activity) from lipid droplets into phospholipid
pools. Disrupting this process derails lipid homeo-
stasis, causing overproduction of toxic saturated ce-
ramides and acyl-carnitines as well as activation of
the NF-kB transcription factor. Our work demon-
strates that triglycerides promote homeostasis by
‘‘buffering’’ specific fatty acids.
INTRODUCTION
Proliferating cancer cells exhibit an increased dependence on
biosynthetic intermediates (Vander Heiden and DeBerardinis,
2017), including fatty acids (FAs) that support the construction
of organelle and plasma membranes. To meet the demand for
elevated FA levels, FA synthase (FASN) overexpression is
commonly observed in multiple cancers (Menendez and Lupu,
2007; Ricoult et al., 2016). Palmitate, the product of FASN enzy-
matic activity, can be further modified by elongation and de-
saturation, where double bonds between carbon atoms are
introduced into long-chain FAs. Stearoyl-coenzyme A (CoA) de-
saturase (SCD), the principal enzyme responsible for desatura-
tion, is critical for sustained viability of a variety of tumor cell2596 Cell Reports 24, 2596–2605, September 4, 2018 ª 2018 The Au
This is an open access article under the CC BY license (http://creativetypes (Igal, 2016). By introducing a double bond into the satu-
rated FA stearate, SCD produces monounsaturated oleate, typi-
cally the most abundant intracellular FA. Although clearly impor-
tant for cell survival, activity of the oxygen (O2)-dependent SCD
enzyme can be constrained by tumor hypoxia (Figure 1A). Pe-
riods of O2 starvation, therefore, lead to a buildup of saturated
FA precursors, causing disruption of endoplasmic reticulum
(ER) membranes and apoptosis (Kamphorst et al., 2013; Young
et al., 2013). Saturated FA-induced toxicity can be alleviated
by supplying exogenous unsaturated lipids (for instance, by
increasing the availability of serum FAs), indicating that lipid up-
take is an important mechanism for maintaining homeostasis in
hypoxic cancer cells (Young et al., 2013).
Accentuated accumulation of neutral lipids in large lipid drop-
lets (LDs) is observed in a subset of tumor types, particularly
clear cell renal cell carcinoma (ccRCC). In ccRCC, this pheno-
type has been linked to genetic loss of the von Hippel-Lindau
(VHL) tumor suppressor, which causes constitutive hypoxia
inducible factor-a (HIFa) stabilization regardless of O2 availabil-
ity. We have previously shown that induction of HIF2a specif-
ically promotes lipid accumulation through upregulation of
PLIN2, the gene encoding the LD coat protein perilipin-2 (Qiu
et al., 2015). PLIN2 loss significantly represses tumor growth,
indicating that LD formation may be driven by HIF2a stabilization
and serves a cytoprotective role in ccRCC. In a separate study,
HIF-dependent repression of FA b-oxidation has also been
demonstrated to contribute to LD accumulation (Du et al., 2017).
LDs are primarily composed of cholesterol esters (CEs) and
triglycerides (TGs), and lipidomic analyses of ccRCC samples
revealed high levels of both in tumors compared with normal
kidney (Saito et al., 2016; Sundelin et al., 2012). TGs consist of
a glycerol backbone and three FAs (Figure 1E), with a significant
diversity in FA chain length and number of double bonds. Their
synthesis requires the activity of the diglyceride acyltransferase
(DGAT) enzymes DGAT1 and DGAT2, which catalyze the
condensation of fatty acyl-CoA with a diglyceride (DG) to form
TG. The two human DGAT enzymes share no homology and
have dissimilar expression patterns (Yen et al., 2008). TGs are
synthesized in the ER, but DGAT2 can also be found on the sur-
face of LDs andmay generate TGs in growing LDs in situ (Wilflingthor(s).
commons.org/licenses/by/4.0/).
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et al., 2013). To mobilize lipid stores to provide FAs, TGs are
broken down by a series of lipases, and the released FAs can,
in principle, be used for incorporation into other lipid types,
such as phospholipids (PLs), or for mitochondrial oxidation.
Although the protective function of LDs and TG turnover have
been identified in a number of contexts (Bailey et al., 2015; Ben-
saad et al., 2014), the full scope of TG synthesis and catabolism
in tumor cells remains unclear.
Here we evaluated the consequences of limiting TG synthesis
in ccRCC. We found that concurrent inhibition of DGAT1 and
DGAT2 severely compromised in vivo tumor growth because
of increased cell death. This was replicated in cultured cells
exposed to low O2 and serum, mimicking a stressful tumor
microenvironment. Mechanistically, TGs sequester exogenous
unsaturated FAs, particularly oleate, when in ample supply.
When oleate availability becomes limiting during O2 and serum
deprivation, however, oleate is instead released into other lipid
pools. This prevents the buildup of fully saturated, toxic lipids
in cellular compartments outside of LDs. Our work reveals a dy-
namic mechanism by which TGs act as buffers for cellular lipid
homeostasis, especially under the tumor-relevant conditions of
O2 and nutrient limitation.
RESULTS AND DISCUSSION
Disruption of TG Synthesis Compromises ccRCC Tumor
Growth
Although the functional roles of CEs in cancer have been interro-
gated to some extent (Yue et al., 2014), TGs have so far remained
considerably less well studied. We investigated how direct
disruption of TG synthesis by loss of DGAT enzymes affects lipid
homeostasis. DGATs appear to carry out mutually redundant
functions in the storage of both endogenously synthesized and
exogenously derived FAs (Figure 1A). We confirmed their redun-
dancy in A498 ccRCC cells by examining the induction of neutral
lipid stores upon administration of oleic acid conjugated with
BSA versus BSA alone. Although a combination of CRISPR/
Cas9-mediated DGAT2 deletion and DGAT1 pharmacological
inhibition fully abrogated this, loss of neither DGAT individually
was sufficient (Figure S1A). This approach provides the opportu-
nity to precisely control the timing of DGAT inhibition by adding
the DGAT1 inhibitor T863 (DGAT1i) to cells with DGAT2 deletion.
Importantly, DGAT deficiency was complemented with a
CRISPR-resistant DGAT2 cDNA, restoring neutral lipid deposi-
tion (Figure S1A). To study the consequences of TG synthesis in-Figure 1. DGAT Loss Reduces Tumor Growth and Alters Lipid Compo
(A) Diagram of fatty acid and lipid synthesis and the influence of O2 and exogeno
(B) Growth curves for A498 xenograft tumorswith induced (doxycycline chow) and
shRNA).
(C) Tumor weights after necropsy.
(D) Immunohistochemistry for cleaved caspase-3 and Ki67 in xenograft tumors c
(E) Total TG abundance derived from summing individual TG species abundance
(F) TG species binned according to the number of fully saturated FA chains pres
doxycycline-treated versus control groups.
All results are means of n = 10 tumors (2 tumors per mouse) per arm; error bars
ANOVA, as appropriate; *p < 0.05, **p < 0.01, and ***p < 0.001. ACC, acetyl-
acyltransferase; FASN, fatty acid synthase; ns, non-significant; PC, phospha
stearoyl-CoA desaturase (inhibitor); SFA, saturated FA; TG, triglyceride; UFA, un
2598 Cell Reports 24, 2596–2605, September 4, 2018hibition in vivo (and employ a complementary approach), we
generated A498 cells expressing both DGAT1 and DGAT2 short
hairpin RNAs (shRNAs) under the control of a Tet-inducible pro-
moter and confirmed that these constructs effectively reduce
DGAT mRNA and protein levels upon doxycycline treatment
(Figures S1B and S1C). After implanting these cells subcutane-
ously in immunocompromised recipients and allowing tumors
to grow to an average size of 300 mm3, mice were fed with either
control or doxycycline-containing chow. A substantial reduction
in both DGAT1 and DGAT2 transcript levels (Figure S1D) and
significantly reduced tumor volume and weight was observed
(Figures 1B and 1C). Immunohistochemical staining of tumor
sections revealed increased numbers of apoptotic cells based
on cleaved caspase-3 staining and decreased numbers of
actively dividing Ki67+ cells (Figure 1D). As anticipated, TG levels
were lower in DGAT-deficient tumors compared with controls
(Figure 1E; Table S1), although the observed differences failed
to reach statistical significance. These results likely reflect the
inherent heterogeneity between cells within solid tumors with re-
gard to TG synthesis and turnover, in addition to variable O2 and
nutrient availability. Nevertheless, a pronounced increase in TGs
containing one or more saturated FAs (R1 saturated FAs [SFAs];
Figure 1F), but not those exclusively carrying unsaturated FAs (0
SFAs; Figure 1F) was observed. Thus, DGAT silencing disrupts
TG FA composition and causes both increased apoptosis and
reduced proliferation of ccRCC tumor cells in vivo.
DGAT Loss Compromises ccRCC Viability in Low O2 and
Serum
We next sought to establish exactly how TG metabolism pro-
motes tumor growth. Because solid tumors are notoriously
poorly perfused and hypoxic (Frantz et al., 2010), we specifically
focused on how serum lipid and O2 limitation results in DGAT
dependency. Of note, combined serum and O2 limitation led to
deteriorated cell viability upon DGAT knockdown (Figure 2A).
Because hypoxia limits SCD activity (Figure S2A) and reduces
cell viability in the absence of exogenous lipid supply (Kam-
phorst et al., 2013; Qiu et al., 2015), we investigated whether
enhanced sensitivity of DGAT-deficient cells to these conditions
is indeed mediated by reduced SCD function. Cells were
exposed to the SCD inhibitor CAY10566, which phenocopied
the effect of O2 deprivation (Figure 2B).
To understand the relationship between serum levels and TG
metabolism, a lipidomic comparison of A498 cells cultured in
either high (5%) or low (0.5%) serum-containing medium wassition In Vivo
us lipid.
un-induced (control chow)DGAT1 andDGAT2 shRNAs (hereafter calledDGAT
ollected on day 5 of treatment, with accompanying quantification.
after liquid chromatography-mass spectrometry (LC-MS) quantification.
ent and the abundance of each category summed and displayed as a ratio of
represent ± SD (B, D, and F) or ± SEM (C). Statistical significance by t test or
CoA carboxylase; CE, cholesterol ester; DG, diglyceride; DGAT, diglyceride
tidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine; SCD(i),
saturated FA. See also Figure S1.
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Figure 2. TGs Promote Cell Viability in Low O2 and Serum by Absorbing FA Saturation
(A) Viability of A498 cells expressing inducible shRNA against DGAT1 and DGAT2 mRNAs (DGAT shRNA), assessed after 72 hr under the indicated conditions
(hypoxia = 0.5% O2; serum deprivation = low serum, 0.5% fetal bovine serum [FBS]) by Annexin-propidium iodide (PI) flow cytometry assay.
(B) Viability of cells expressing inducible DGAT shRNAs after 72 hr under the indicated conditions (SCDi, 1 mM CAY10566) by Annexin-PI assay using flow
cytometry.
(C) Volcano plot showing fold change and significance of alterations in the lipidome of A498 cells cultured in low (0.5%) versus high (5%) serum. Lipids
withR 1.5 fold change and p% 0.05 are displayed in color to denote lipid class.
(D) Changes in FA composition or saturation of TGs, calculated by aggregating TG abundances for species containing 0, 1, or 2+ SFA chains separately. Values
are normalized to control conditions (5% serum).
(E) Lipid class-specific saturation indices (defined by (palmitate + stearate) / oleate) for A498 cells cultured under hypoxic (0.5% O2) versus normoxic conditions
(both in low serum).
(F) As (E) but with pharmacological SCD inhibition (1 mM CAY10566) instead of hypoxia.
(G) Effect of serum deprivation and DGAT shRNA on total TG abundances.
(H) Changes in FA makeup of TGs following DGAT knockdown; values were calculated by aggregating TG abundances for species containing 0, 1, or 2+ SFA
chains separately. Values were normalized to the control condition (vehicle [Veh] treatment).
(legend continued on next page)
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performed, revealing substantial remodeling of the intracellular
lipid composition. Among the most pronounced changes were
significant reductions in CEs as well as in TGs (Figure 2C).
Limiting serum in vitro led to large decreases in the abundance
of unsaturated TGs (Figure 2C) and a shift toward TG saturation
(Figure 2D), as noted for solid tumors (Figures 1E and 1F). A strik-
ing depletion in neutral lipid stores was also confirmed by boron-
dipyrromethene (BODIPY) imaging (Figure S2B), in line with
earlier observations (Bensaad et al., 2014). This indicates that,
in addition toHIF signaling, availability of exogenous serum lipids
is critical for maintaining abundant lipid stores. Increased TG
storage observed under hypoxia appears to be cytoprotective
and renders cells more resistant to subsequent hypoxia and
hypoxia-reoxygenation-mediated cytotoxicity (Bensaad et al.,
2014). Moreover, TGs may also harbor polyunsaturated FAs to
protect them against peroxidation (Bailey et al., 2015). To estab-
lish whether lipid stores ‘‘buffer’’ against lipid saturation in our
system, we determined whether any one class of lipid preferen-
tially ‘‘absorbs’’ alterations in FA saturation under hypoxia. Strik-
ingly, TG composition was affected much more profoundly than
other lipid classes (Figures 2E and S2C), including a loss of
TGs harboring unsaturated FAs and a shift toward increased
TG saturation (Figure S2D). Moreover, these changes were
only observed under low-serum conditions. When A498 cells
were exposed to pharmacological SCD inhibition instead of hyp-
oxia (Figure S2E), we observed a similar but more pronounced
increase in TG saturation (Figure 2F) as well as a stronger effect
on other lipid classes (especially DGs), the direct precursors
for TGs. This difference is most likely due to a combination of
more potent SCD inhibition by pharmacological approaches
compared with hypoxia (leading to increased FA saturation) as
well as a limited capacity of TGs to cope with the increased FA
saturation, leading to ‘‘spill-over’’ into other lipid classes. Impor-
tantly, when other ccRCC cell lines (786-O and UMRC2) were
exposed to lowO2, FA saturation was similarly most pronounced
in TGs, followed by the direct precursor DGs (Figures S2F and
S2G). This suggests that TGs have a capacity to promote cell
viability by balancing the availability of specific FAs.
Serum deprivation reduced intracellular TG abundance (Fig-
ure 2G), in keeping with the BODIPY imaging depicted in Fig-
ure S2B. As demonstrated with in vivo tumor growth (Figures
1E and 1F), DGAT silencing in vitro also caused a further
decrease in TG abundance (Figure 2G) and selective depletion
of unsaturated TGs (Figure 2H). Given that both hypoxia and
DGAT depletion cause increased saturation of the TG pool under
low-serum conditions, we asked whether combination of the two
leads to a cumulative effect; i.e., an even more saturated TG
pool. Indeed, in the setting of low serum availability, O2 depriva-
tion or pharmacological SCD inhibition increased TG saturation
(Figures 2I and 2J). Again, more potent pharmacological SCD in-
hibition (compared with hypoxia) resulted in increased TG satu-
ration relative to O2 starvation. Additional DGAT knockdown
further lowered TG levels (Figure 2G), resulting in an even more(I) TG saturation indices for the indicated conditions. Values are relative to normo
(J) As (G) but with pharmacological SCD inhibition (1 mM CAY10566). Values are
Data are means of 3 (A, B, and D–J) or 5 (C) replicate wells and were confirmed in
t test or ANOVA, as appropriate. **p < 0.05, and ***p < 0.005. See also Figure S2
2600 Cell Reports 24, 2596–2605, September 4, 2018saturated TG pool (Figures 2I and 2J). These results highlight a
protective role of LDs under serum- and O2-limited conditions
through buffering cellular FA saturation.
TGs Neutralize Excess Fatty Acid Saturation through
Release of Stored Oleate
Although the aforementioned protective role of TGs could simply
be due to their ability to sequester excess saturated FAs into
TGs, TG synthesis by DGAT enzymes is more efficient when
the substrates are unsaturated rather than saturated (Listen-
berger et al., 2003). LDs could alternatively protect cells by pref-
erentially releasing unsaturated FAs from stored TGs for use in
the production of cytosolic and membrane-associated lipids.
Because monounsaturated oleate (C18:1) is the single most
abundant FA in TG pools (Figure S3A), its mobilization during pe-
riods of unsaturated lipid deprivation should ameliorate stress by
preventing the synthesis of fully saturated, potentially toxic
lipids. A498 cells experiencing stringent conditions of low serum
and pharmacological SCD inhibition exhibited reduced total TG
levels (Figure 3A), supporting this hypothesis. To further test
this, we assessed the protective potential of oleate, which is
efficiently incorporated into TGs and, consequently, the most
abundant TG FA. A498 cells were pre-treated with oleate under
low-serum conditions before being exposed to SCD inhibition.
Oleate pre-treatment indeed promoted cell viability under these
conditions (Figure 3B), which was largely abolished upon DGAT
silencing, suggesting that it occurs through TGs.
To study the cellular fate of oleate in more detail, we designed
a washout labeling approach (Figure 3C; see STAR Methods for
information about lipid tracing). Serum-starved and, hence, LD-
depleted A498 cells were first exposed to labeled [U13C]-oleate
in the ‘‘loading’’ phase. We employed cells with DGAT2 loss
induced through CRISPR/Cas9-mediated mutagenesis (Fig-
ure S1A) to again precisely time DGAT inhibition by adding
DGAT1i. Following loading, the [U13C]-oleate tracer was
removed, and [U13C]-oleate in the TG pool was left to ‘‘wash
out,’’ allowing its fate (such as re-incorporation into other lipid
classes) to be determined. Mass spectrometry analysis of TGs
post-loading but pre-washout demonstrated that oleate was
avidly incorporated into TGs, mostly producing TGs with three
oleate FAs (Figure 3D; i.e., 33 [U13C]-18:1 versus 23 or 13
[U13C]-18:1). Similarly, BODIPY imaging of neutral lipid stores
was used to confirm that oleate loading led to abundant TG
accumulation, largely prevented by DGAT inhibition (Figure 3E).
Moreover, a non-negligible amount of [U13C]-oleate (C18:1)
was elongated to [13C18]-20:1 (i.e., a C20:1 FA with 18
13C) prior
to its incorporation into TGs like TG (56:3) (Figure 3D; data not
shown). As expected, DGAT inhibition severely limited the incor-
poration of labeled oleate into TGs.
Based on our data, we reasoned that, under conditions of
saturated FA excess, TG oleate mobilization and subsequent
re-esterification into other lipid classes enables continued pro-
duction of lipids with at least one unsaturated FA, preventingxic untreated cells.
relative to the untreated vehicle control.
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Figure 3. 13C-Oleate Tracing Reveals a Critical Buffering Role for TG-Resident Unsaturated FAs
(A) Effect of SCDi on total TG abundances as measured by LC-MS.
(B) Effect of oleate pre-loading with or without DGAT shRNA on subsequent A498 cell survival (by Annexin-PI) during serum limitation and SCD inhibition.
(C) Schematic of the experimental workflow. DGAT2 knockout cells were serum-starved for 24 hr and then loaded for 24 hr with 10 mM [U13C]-oleate (C18:1) ±
DGAT1 inhibitor (T863, 2 mM). The medium was then replaced and the tracer removed, and cells were subjected to a 48-hr washout.
(D) TG labeling patterns after 24-hr loading with [U13C]-oleate with or without DGATi, where numbers of mono-unsaturated FA (MUFA) and FA carbons are
indicated. 13, 23, and 33 indicate whether TGs have one, two, or three oleates (includes [13C18]-20:1) conjugated to their glycerol backbones.
(E) BODIPY and DAPI staining directly after [U13C]-oleate loading with or without DGATi.
(F) Labeling patterns as assessed by incorporation of the 13C label in 18:1 and 20:1 FAs in TG, DG, PC, and PE species.
(legend continued on next page)
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the synthesis of harmful, fully saturated lipids. To evaluate the
dynamics of oleate redistribution to other lipid species, changes
in bulk [U13C18]-18:1 and [U
13C18]-20:1 in TGs, DGs, and mem-
brane phospholipids, phosphatidylcholines (PCs) and phospha-
tidyl ethanolamines (PEs), were analyzed after a 48-hr washout in
low serum (Figure 3F). In accordance with total TG levels (Fig-
ure 3A) and BODIPY imaging (Figure 3E), cells loaded with
labeled oleate (0 hr, DGAT1i) exhibited a strong reduction in
TG FA labeling over the course of the washout (48 hr). Cells
treated with DGAT1i during loading had lower labeled FA levels
to start, which were almost entirely depleted during washout
(Figure 3F). Analysis of DG, PC, and PE lipids indicated that
[U13C18] mono-unsaturated FAs (MUFAs) were incorporated
into all three classes during loading. Because the exogenous
[U13C]-oleate tracer was removed at the start of washout, we ex-
pected levels of labeled FAs in these lipids (as for TGs) to
diminish because of continuous turnover. This was evidently
the case for the DGAT1i-treated cells because at least a 2-fold
reduction in labeling was observed. Strikingly, this reduction
was not detected in untreated cells, most likely because oleate
originally loaded in the TG pool is subsequently feeding into
DG, PC, and PE lipid pools during washout. By reducing the
TG pool, DGAT inhibition prevents the subsequent flow of oleate
from TGs to other lipid classes during periods of unsaturated
lipid deprivation
Adipose triglyceride lipase (ATGL) and monoacylglycerol
lipase (MAGL) have been shown previously to play supportive
roles in cancer progression (Nomura et al., 2010; Zagani et al.,
2015), suggesting that mobilization of TG stores is critical for
tumor cell metabolism. We investigated the outcome of pharma-
cological inhibition of TG hydrolysis (Figure S3B) and did not
observe appreciable effects of disrupting ATGL or MAGL activity
on the flow of labeled oleate from TG into other lipid types (see
STAR Methods for experimental details). In contrast, inhibition
of hormone-sensitive lipase (HSL) led to accumulation of labeled
DG, in accordance with its ascribed function as a DG lipase (Fig-
ure S3B). HSL inhibition also substantially reduced the washout
of TG labeling and caused more abundant PC labeling than in
untreated cells. The effects of HSL inhibition were confirmed in
two additional ccRCC cell lines (Figure S3C), consistent with
DG’s role as a substrate for PL synthesis. Of note, in 786-O cells,
almost no labeled FAs were left in the TG pool at the end of the
washout experiment, suggesting that the FA buffering capacity
in this cell line is somewhat more limited. This is consistent
with the more pronounced saturation of the DG pool upon
cellular stress (Figure S2F) and our observation that these cells
have lower LD numbers under our conditions (data not shown).
Our findings demonstrate that oleate (and, to a lesser degree,
its elongated C20:1 product) can be released from the TG pool
to feed into other lipid classes and most likely requires HSL to
break down DGs produced by TG hydrolysis.
Based on our extensive labeling studies of TG turnover under
different growth conditions, we propose that TGs act as a buffer(G) Model of themetabolicmechanism bywhich TGs alleviate the saturation of cer
releasing stored oleate.
Data aremeans of triplicate wells confirmed in independent experiments (A, B, and
error bars represent SD. Statistical significance by t test or ANOVA, as appropria
2602 Cell Reports 24, 2596–2605, September 4, 2018for unsaturated FA (mostly oleate; Figure 3D) availability (Fig-
ure 3G). During exposure to high serum lipid and/or oleate levels,
cells store large amounts of oleate in TGs via DGAT activity.
When transitioning to a low-serum environment, TG pools shrink
because of HSL-mediated hydrolysis, and released oleate re-
plenishes other lipid species. This helps maintain a viable FA
composition when cells are additionally experiencing excess
FA saturation, as occurs during tumor hypoxia.
Compromised FA Buffering by TGs Causes Diversion of
Saturated FAs into Toxic Ceramides and Acyl-carnitines
Because ceramides are predominantly generated from
saturated FAs, and excess buildup promotes apoptosis, we
investigated their abundance following DGAT inhibition. DGAT
depletion resulted in a large increase in ceramide levels in
A498 cells treated with SCD inhibitor under serum-deprived con-
ditions (Figure 4A) and A498 xenograft tumors (Figure 4B), along
with acyl-ceramides (Figure 4C). Acyl-carnitines have recently
been shown to be elevated upon DGAT inhibition, contributing
to mitochondrial dysfunction (Nguyen et al., 2017). In line with
this, we observed elevated acyl-carnitine upon DGAT knock-
down in the context of in vitro hypoxia (Figure 4D), in vitro SCD
inhibition (Figure 4E), and in vivo xenograft tumors (Figure 4F).
These changes indicate that disrupted TG synthesis widely
affects lipid homeostasis and accumulation of toxic lipid
species.
To further evaluate the effects of decreased cellular lipid ho-
meostasis through DGAT loss, we performed both in vivo and
in vitro microarray studies. A498 tumor samples harboring
DGAT shRNA were compared with controls, and a gene set
enrichment analysis (GSEA) was performed (Figure 4G). A par-
allel analysis of A498 cells grown under 0.5% serum and
exposed to either 21% O2 or 0.5% O2 for 48 hr, with or without
induction of DGAT shRNA expression, was also performed
(Figures S4A and S4B). The expression of transcriptional tar-
gets of nuclear factor kB (NF-kB) exhibited a striking pattern
of regulation that suggests induction by lipid dysregulation.
In vivo, DGAT depletion led to a significant increase in NF-kB
target gene expression (Figure 4G). In vitro, the same gene
set was enriched by hypoxia, DGAT loss, and the combination
of these two treatments under serum deprivation (Figures S4A–
S4C). Of note, we observed a stepwise increase in many NF-kB
target gene mRNAs by sequentially combining DGAT loss and
hypoxia (Figure S4D). NF-kB is known to be engaged under
conditions of stress and excess saturated FA exposure (Van
Beek et al., 2012; Carluccio et al., 1999; Massaro et al.,
2002), regulating desaturase activity and ovarian cancer stem
cell identity (Li et al., 2017). We therefore hypothesized that
the elevated lipid saturation detected in DGAT-depleted tumors
engages the NF-kB pathway. Using a luciferase reporter, we
confirmed that both basal and tumor necrosis factor a
(TNF-a)-induced NF-kB activity was enhanced by DGAT
loss in A498 cells (Figure 4H). Importantly, NF-kB pathwaytain lipid classes (e.g., PCs) under conditions of unsaturated lipid deprivation by
D) ormeans of three independent experiments each conducted in triplicate (F);
te. *p < 0.05, **p < 0.05, and ***p < 0.005. See also Figure S3.
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Figure 4. DGAT LossModifies Lipid Homeostasis, Elevates Ceramide, Acyl-ceramide, and Acyl-carnitine Levels, and Activates NF-kB Target
Gene Expression
(A) Effect of SCD and DGAT inhibition on ceramide levels in serum-deprived A498 cells in vitro.
(B) Effect of DGAT loss on ceramides in vivo (i.e., A498 xenografts).
(C) Effect of DGAT loss on acyl-ceramides in vivo (i.e., A498 xenografts).
(D) Effect of hypoxia on the FA composition of acyl-carnitines (CARs) on serum-deprived A498 cells in vitro.
(E) Effect of DGAT loss on the FA composition of acyl-carnitines (CARs) on serum-deprived A498 cells in vitro.
(F) Effect of DGAT loss on the FA composition of acyl-CARs in A498 xenograft tumors.
(legend continued on next page)
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engagement was inhibited by the specific NF-kB inhibitor
PS-1145 (Figure 4H) as well as the proteasome inhibitor ixazo-
mib. Of note, ixazomib inhibits NF-kB by stabilizing its negative
regulator inhibitor of kB (IkB) (Mujtaba and Dou, 2011). Serum
deprivation also led to increased NF-kB reporter activity, which
was fully inhibited by administration of both PS-1145 and ixa-
zomib (Figure 4I). Collectively, our data suggest that DGAT defi-
ciency leads to broad disruption of lipid homeostasis, resulting
in unsaturated FA depletion and accumulation of saturated FAs
and, consequently, ceramides, acyl-ceramides, and acyl-carni-
tines (Figure 4J). This is accompanied by activation of NF-kB
signaling, previously documented to respond to increased
saturated FAs. Future work will delineate whether NF-kB
signaling contributes to balancing FA availability during stress-
ful conditions as a prosurvival mechanism.
Altered TG Saturation in ccRCC Patient Samples
Given the requirement for DGAT activity to survive conditions of
excess lipid saturation in our experiments, we determined
whether this is a common feature of human tumor biology. We
therefore re-analyzed published data comparing the TG compo-
sition of ccRCC patient samples and normal kidney tissues
(Saito et al., 2016). As expected, TG levels were strongly
elevated in ccRCC, as documented previously (Sundelin et al.,
2012). However, the fold change was particularly pronounced
for TGs containing one ormore SFAs, demonstrating an increase
in TG saturation (Figure 4K). This increase in ccRCC TG satura-
tion is consistent with TG regulation of FA composition in lipid
pools, as observed in our in vitro experimental system (Figures
3E and 3F). We therefore suggest that increased FA saturation
(and its buffering by TGs) occurs in tumor samples derived
from ccRCC patients.
Conclusion
Although oncogenic signaling alters cellular metabolism to pro-
mote the synthesis of macromolecules, malignant cells are
also programmed to withstand nutrient scarcity (Boroughs and
DeBerardinis, 2015). This metabolic flexibility can involve the in-
duction of scavenging pathways, such as autophagy in RAS- or
BRAF-driven cells (Yang et al., 2011) or macropinocytosis in
KRAS-driven cells deprived of glutamine (Commisso et al.,
2013). Both KRAS and hypoxia promote the uptake of extracel-
lular unsaturated lipids with similar consequences: cells become
more resistant to O2 deprivation and its associated inhibition of
FA desaturases (Kamphorst et al., 2013). Here, in the case of
LDs, hydrolysis of unsaturated TGs supplies unsaturated DGs(G) Gene set enrichment analysis (GSEA) on RNA as assessed by microarray co
control or doxycycline chow. Normalized enrichment score (NES) allow compari
(H) Effect of DGAT shRNA, NF-kB inhibition, and proteasome inhibition on NF-kB
(I) Effect of serum deprivation on NF-kB luciferase reporter activity.
(J) Schematic of the consequences of DGAT inhibition preceding a period of uns
ceramides as well as increased incorporation of saturated FAs into the PL pool.
(K) Published data comparing the TG composition of ccRCC and normal tissue
species were binned according to the number of fully saturated FA chains presen
ratio of the abundance in normal tissue.
For (A), (D), (E), data aremeans of 5 and for (H) and (I) of 3 replicate wells, and result
means of tumors from 4 tumors. Error bars represent SD. Statistical significance
also Figure S4.
2604 Cell Reports 24, 2596–2605, September 4, 2018and FAs as substrates for PL synthesis, maintaining lipid homeo-
stasis during periods of increased FA saturation. We therefore
propose that unsaturated FA storage in TGs contributes to
ccRCCmetabolic plasticity and that its inhibition may effectively
target cancer cells residing in ischemic tumor domains
(Figure 4J).
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Subcutaneous xenograft experiments were approved by the Animal Care and Use Committee at the University of Pennsylvania.
10 Female NIH-III nude mice (Charles River; 4–6 weeks old) were injected subcutaneously in both flanks. The injection mix contained
5 million cells in PBS, mixed 1:1 with Matrigel Basement Membrane Matrix (Corning). Tumor volume was monitored by caliper mea-
surements. After tumors reached 300 mm3, mice were split into cohorts of 5 mice receiving doxycycline chow (200 mg/kg; Harlan
Labs) or control chow (Harlan Labs) ad libitum. After experiment completion, animals were sacrificed by CO2 inhalation, and xeno-
graft tumors were dissected for downstream analyses.
Cell Lines and cell culture conditions
Authenticated (short tandem repeat profiling) human cell lines HK-2, 786-O, 769-P, A498, RCC4, RCC10, UOK101, andUMRC2were
obtained from the American Type Culture Collection. Cell lines were routinely passaged in DMEM (GIBCO) with 25 mM glucose and
2 mM L-glutamine with 5% (v/v) fetal bovine serum (FBS, GIBCO) at 37C and 5% CO2. Cells were split at 80% confluency. All cell
lines described in this study were verified mycoplasma-negative. Experiments were performed in DMEM supplemented with 10 mM
glucose, 2 mM L-glutamine and indicated levels of FBS (Sigma). Hypoxic conditions were maintained at 0.5%O2, 37
C and 5%CO2
in the InVivO2 Hypoxia Workstation with a Ruskinn Gas mixer Q (Baker Co.). Cell number was assessed using the Countess Cell
Counter (ThermoFisher) or estimated using packed cell volume (PCV, Sartorius Volupac), as appropriate.Cell Reports 24, 2596–2605.e1–e5, September 4, 2018 e2
METHOD DETAILS
13C-FA tracing
For the [U13C]-oleate washout experiment, DGAT2 knockout A498 cells were seeded in 6-well plates and serum starved in DMEM
containing 0.5%dialyzed FBS for 24h. Themediumwas then replacedwith newmedium containing 10 mM [U13C]-oleate (Sigma) with
or without DGAT1i (T863, 1 mM) and incubated for 24h. The medium containing [U13C]-oleate was replaced with fresh medium (0.5%
dFBS). Cells were incubated for 48h in these conditions followed by lipid extraction as described in Lipid extraction and liquid chro-
matography - mass spectrometry (LC-MS) analysis, below. The tracing experiment was repeated three times independently with
each condition conducted in triplicate.
qRT-PCR studies
Total RNA was isolated using the RNAeasy purification kit (QIAGEN). cDNA was synthesized using the Applied Biosystems High
Capacity RNA-to-cDNA master mix. qRT-PCR was performed on a ViiA7 Real Time PCR systems from Applied Biosystems. Pre-
designed Taqman primers were obtained from Life Technologies for the following genes: TBP (HS01060665_G1), ACTB
(HS01060665_G1), DGAT1 (HS01017541_M1), and DGAT2 (HS01045913_M1).
DGAT mutant and knockdown lines
DGAT1 and DGAT2 shRNA (specified as DGAT shRNA unless stated otherwise) was achieved by expressing Dox-inducible
shDGAT2_5 (TRCN0000005195) using the Tet-pLKO-puro plasmid and shDGAT1_1 (TRCN0000036151) using the Tet-pLKO-neo.
Lentivirus was generated for each plasmid in HEK293T cells and used to infect the relevant cell line. After selection with puromycin
and G418, the knockdown of both DGAT1 and DGAT2 transcripts was confirmed by qRT-PCR (Taqman probes; ThermoFisher)
DGAT2 knockout cell lines were generated by cloning sgRNA sequences 50-TGTGCTCTACTTCACTTGGC-30 and 50-GTACATGAG
GATGGCACTGC-30 into the lentiviral vector lentiCrisprv2 (Addgene), generating lentivirus in HEK293T cells and transducing ccRCC
cell lines with 25ml of un-concentrated supernatant. After puromycin selection, single cell clones were generated by limiting dilutions
in 96 well plates. Single-cell clones were expanded and genomic DNA was isolated from a portion of the expanded cell population.
PCR of the DGAT2 locus was performed using DA182 (TCCTCTTGTCCCAGGAATCTGC) forward and DA184 CACTCAGGAT
GAGGCCCTTCAG reverse primers. PCR products were TOPO-cloned using the Zero Blunt PCR cloning kit (ThermoFisher) and
transformed into competent E. coli. For each clone, 3-6 colonies were picked and grown overnight in LB-Ampicillin. Plasmid DNA
was isolated using the QiaPrep Miniprep kit (QIAGEN) and sequenced using a nested primer DA183 (GAATCTGCTCC
TACCTGGGCTG). Clones containing mutations in both alleles were tested phenotypically by Bodipy neutral lipid staining, and
LC/MS confirmed reduced TG production (data not shown), as expected. Cells were incubated with 1:50 dilution of oleic acid-
BSA mix (Sigma; 2 mole OA/mole albumin; 100mg/ml albumin) for 16h with and without the presence of 2 mM DGAT1i
(T863, Sigma). Clonal lines with full loss of DGAT2 activity loss had complete abrogation of neutral lipid storage by oleic acid
stimulation when DGAT1 was inhibited. Rescue of DGAT2 loss was performed by cloning DGAT2 cDNA from the pcDNA3.1 vector
(GeneCopoeia) into the pCDH lentiviral expression plasmid pCDH-CMV-MCS-EF1-Neo using the primers DA199 (GTTTCTgctag
cATGAAGACCCTCATAGCCGC), DA200 (GTTTCTgcggccgcTCAATGGTGATGGTGATGATG) as well as DA199 and DA201
(gtttctGCGGCCGCtcaGTTCACCTCCAGGACCTCAG) for expression with and without V5 and Histags. gRNA sites were then
mutated to prevent cutting by Cas9 protein expressed in the mutant cell lines. Synonymous mutations were introduced using
DA187 (TACTGGGAGTGGCaTGCAGTGCCAT) and DA188 (ATGGCACTGCAtGCCACTCCCAGTA).
Flow cytometry assays
For experiments, cells were seeded in 6-well plates 24 hours before the experiment at a cell density that led to 80% confluency at the
end of the experiment. BODIPY 493/503 (Cat D3922) was purchased from Life Technologies and FITC–Annexin V, PI Kit (cat. 556547)
from BD Biosciences. Live cells were washed twice in PBS and incubated in 2 mg/ml BODIPY in PBS for 15 minutes at 37C. After
staining, cells were washed twice in PBS and re-suspended in Annexin-V binding buffer (BD Cat 556454), passed through a cell
strainer, and analyzed on an Accuri C6 flow cytometer. For viability assays, cells were stained with FITC-Annexin V and PI according
to the manufacturer’s instructions and double-negative cells were deemed viable. Median signal intensity for each well was average
for triplicate samples to determine staining intensity.
Lipid droplet imaging
Cells were seeded on round glass coverslips of 24-well plates and supplemented with 1 mL of medium and exposed to the indicated
conditions. The medium was then aspirated, cells washed once with 1 mL room temperature PBS, fixed with 0.5 mL of 4% formal-
dehyde (Sigma) for 30 min after which excess was removed and cells washed 3x with 1 mL PBS. Cells then were incubated with
0.3mL of 1 mM BODIPY 493/503 (Life Technologies) (excitation wavelength 480nm, emission maximum 515 nm) for 15 min in the
dark, washed 2x with 1 mL PBS, incubated with 0.3 mL of 1 mg/mL DAPI (Sigma) for 15 min in the dark and washed 2x with 1 mL
PBS. Thereafter, the coverslips were mounted on glass slides using Dako Fluorescent Mounting Medium (Dako). Z stack images
were acquired using Olympus FV1000 confocal laser scanning microscope (405 nm laser for DAPI and 488 nm laser for BODIPY)
and processed with ImageJ software.e3 Cell Reports 24, 2596–2605.e1–e5, September 4, 2018
Lipid extraction and liquid chromatography - mass spectrometry (LC-MS) analysis
For cultured cells themediumwas aspirated and cells washed 2x with 1mL room temperature PBS. The cells were placed on ice and
quenchedwith 0.75mL of methanol/PBS (1:1, v/v) at20C, and kept for 10min. The cells were then scraped into glass tubes (Fisher
Scientific), 0.5 mL chloroform at 20C (Sigma) and 50 mL of 1 mg/mL methanolic butylated hydroxytoluene (BHT, Sigma) added,
followed by addition of SPLASH lipidomix internal standard mix (Avanti Polar Lipids) at 1 mL per 1*105 cells. This was vortexed for
1 min and centrifuged at 500g for 10 min. The chloroform layer was transferred to a new glass vial, dried under nitrogen gas and
stored at 20C for further LC-MS analysis. Samples were reconstituted in chloroform/methanol (1:1 v/v) at 50 mL per 1*105 cells
prior to the LC-MS analysis.
For extraction of tumor tissues, 10-35 mg was transferred to ice-cold Precellys lysing tubes, 0.75 mL of methanol/PBS (1:1, v/v)
at 20C and 50 mL of 1 mg/mL BHT in methanol added, and homogenized using pre-cooled Precellys Tissue Homogenizer
at10C. The homogenization program included 3 cycles of 30 s of shacking at 5,000 rpm and 15 s pause per cycle. Further sample
treatment was as for cultured cells, with addition of 0.5 mL chloroform at20C and internal standard mix at 10 mL per 10 mg tissue.
Samples were reconstituted at a concentration of 200 mL per 10 mg of tissue in chloroform/methanol (1:1 v/v) prior to the LC-MS
analysis.
Lipidomic analysis was performed using a Q Exactive orbitrap mass spectrometer coupled to a Dionex UltiMate 3000 LC system
(Thermo Scientific). The LC parameters were as follows: 4 mL of sample was injected onto a 1.7 mm particle 1003 2.1mm ID Waters
Acquity CSH C18 column (Waters) which was kept at 50C. A gradient of (A) water/acetonitrile (40:60, v/v) with 10 mM ammonium
formate and (B) acetonitrile/2-propanol (10:90, v/v) with 10 mM ammonium formate at a flow rate of 0.3 mL/min was used. The
gradient ran from 0% to 40% B over 6 min, then from 40% to 100% B in the next 24 min, followed by 100% B for 4 min, and then
returned to 0% B in 2 min where it was kept for 4 min (40 min total). Lipids were analyzed in both positive and negative mode.
The electrospray and mass spec settings were as follows: spray voltage 3 kV (positive mode) and 3.5 kV (negative mode), capillary
temperature 300C, sheath gas flow 50 (arbitrary units), auxiliary gas flow 7 (arbitrary units) and sweep gas flow 5 (arbitrary units). The
mass spec analysis was performed in a full MS and data dependent MS2 (Top 10) mode, with a full scan range of 300-1200 m/z, res-
olution 70,000, automatic gain control at 1x106 and a maximum injection time of 250 ms. MS2 parameters were: resolution 17,500,
automatic gain control was set at 1x105 with a maximum injection time of 120ms.
Lipase inhibitor assays
A498, 786-O or UMRC2 cells were grown in 0.5% serum (low serum) for 24h, then loaded with 10 mMU-13C oleate for 24h incubation
under low serum. Labeled oleate was washed out by growing cells under low serum for 48h with or without addition of a lipase in-
hibitor. ATGL inhibitor atglistatin (Sigma SML1075) was used at 50 mM, HSL inhibitor CAY10499 (Cayman chemicals) was used at
50 mM and MAGL inhibitor JJKK048 (Tocris) was used at 50 mM. Cells were then counted and harvested for lipidomic analysis.
Microarray experiments
For in vivo analysis of gene expression following inducible DGAT knockdown, mice bearing 300mm3 tumors from subcutaneously
injected A498 DGAT shRNA cells were fed either doxycycline- or control- chow for 5 days. The animals were then sacrificed, the
tumors harvested and RNA was extracted using the RNEasy kit (QIAGEN). RNA was then deposited with the University of Pennsyl-
vania Molecular Profiling core facility for processing, microarray analysis using the Affymetrix HTA 2.0 Chip and analysis.
Suitability of using 13C-labeled FAs to study lipid metabolism
FAs supplied to cells can be used for oxidation to generate energy, can directly be incorporated into lipids, or can first be further
matured (i.e., elongated, desaturated) prior to lipid assembly. Oxidation of 13C-labeled FAs leads to generation of 13C-acetyl-
CoA, which in turn can be used for the synthesis of new FAs. This would lead to complex labeling distributions that would complicate
interpretation of labeling patterns and hence lipid metabolic events. To determine the feasibility of using 13C-FAs to study lipid meta-
bolism, A498 cells were incubated for 6 hours with 25 mM [U13C]-stearate (C18:0) and labeling of triglycerides was assessed (Fig-
ure S5A). This short time spanwas sufficient to generate extensively labeled TGs. Notably, after correcting for natural 13C occurrence,
the majority of TG isotopologs observed were the unlabeled (M0), the M+18 isotope corresponding to the incorporation of one [U13C]-
C18:0, as well as M+36 and M+54 that result from the incorporation of 2 and 3 labeled FAs, respectively. Some minor odd-labeled
isotopes (M+19, M+37, M+55) were observed; these are most likely caused by imperfect corrections for 13C-natural abundance by
the algorithm. Importantly, no significant partial labeling was observed, demonstrating that FA synthesis from 13C-acetyl-CoA due
to FA oxidation is not detectable and does not complicate FA tracing experiments.
Fragmentation spectra of labeled TGs further confirmed that labeled FAs shorter than 18 carbons do not occur. This is arguably
best demonstrated by the MS2 pattern of TG(48:0) M+18 (one labeled FA, Figure S5B). While one could assume that TG(48:0) is
primarily made up of 3x C16:0 (palmitate), the fragmentation pattern actually reveals a mixture of FA compositions, which each com-
bination totaling 48 carbons (16:0/16:0/16:0, 16:0/18:0/14:0, 12:0/18:0/18:0). This means that these TGs have the samemass and do
not separate by LC-MS. While this should be kept in mind, it does not affect interpretation of the labeling pattern. Importantly, in
TG(48:0) M+18 and other TGs (data not shown) only [U13C]-C18:0 is observed and no shorter 13C-FAs, further demonstrating that
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We did find that Labeled stearate is desaturated and elongated leading to FAs such as [U13C]-18:1 and [13C18]-20:0 as well
as longer chain FAs, as evidenced by the direct observation of their acylium ions in MS2 (FAs are observed as their acylium ions
in positive mode MS2, Figure S5C). We therefore concluded that tracing with 13C-labeled FAs is suitable for investigating the
dynamics of lipid metabolism.
QUANTIFICATION AND STATISTICAL ANALYSIS
Lipidomic data processing
Peak detection, peak area quantification, lipid identification, and alignment were performed using LipidSearch (Thermo Fisher
Scientific/Mitsui Knowledge Industries) with standard settings for Q Exactive Product Search. Data was then exported to Excel
and lipid peak areas were normalized to the peak area of the corresponding lipid internal standard using an in-house R script.
The normalized peak areas of identified lipids were used for plotting.
Volcano plots were generated using ggplot2 R package by plotting log Fold change (n = 5 for each condition) against –log P value
(Wickham, 2009). Significant changes withR 1.5-fold and p% 0.05 are indicated in color according to the figure legend.
Saturation indices for different lipid classes are represented as a ratio of total palmitate and stearate to oleate. The total level of
palmitate in individual lipid class was calculated by summing up the intensities of each palmitate-containing lipid multiplied by the
number of palmitate moieties in each lipid (i.e., total palmitate in TG = S (1*TG(16:0/18:0/18:1) + 2*TG(16:0/16:0/18:1) +3*TG(16:0/
16:0/16:0))). The same principle was used for calculation of total stearate and oleate.
For stable isotope tracing experiments MAVEN software was used. A total 13C-FA incorporation value for each lipid class was
calculated by summing up the labeling intensities for those lipids of that class that were most intensely labeled and together
containedR 80% of total label. A labeling intensity per lipid was calculated by summing up the intensities for each labeled isotope
multiplied by the number of labeled FAs for that particular isotope (i.e., total labeling = S (1*M+18 + 2*M+36 +3*M+54)).
Statistical Analysis
For bar plot, the height of the bar represents the mean of all replicates and error bars represent ± SD or ± SEM, as indicated in the
Figure Legends and Supplemental Figure Legends. Replicate numbers, statistical tests used and explanations for error bars are
indicated in the Figure Legends and Supplemental Figure Legends. Statistical significance was derived using R or GraphPad Prism
7.0 by t test or ANOVA, as appropriate; *p < 0.05, **p < 0.01 and ***p < 0.001.
DATA AND SOFTWARE AVAILABILITY
The A498DGAT shRNA in vivomicroarray experiment and the A498DGAT shRNA in vitromicroarray experiment data were deposited
at NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/) under accession numbers GEO: GSE117774 and GSE117775 respectively.e5 Cell Reports 24, 2596–2605.e1–e5, September 4, 2018
